We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ETX E-therapeutics Plc

0.01 (0.11%)
06 Dec 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
E-therapeutics Plc LSE:ETX London Ordinary Share GB00B2823H99 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.01 0.11% 9.05 39,733 16:35:19
Bid Price Offer Price High Price Low Price Open Price
9.00 9.10
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 475k -8.27M -0.0142 -6.37 52.78M
Last Trade Time Trade Type Trade Size Trade Price Currency
15:59:17 O 20,000 9.0048 GBX

E-therapeutics (ETX) Latest News

E-therapeutics (ETX) Discussions and Chat

E-therapeutics Forums and Chat

Date Time Title Posts
23/11/202307:35E-Therapeutics ETX : Applying AI / ML to drug discovery & development957
13/9/202013:39ETX : Stocktube Vid75
13/9/202013:39ETX, The Boss & the Company3
13/9/202013:39ETX-Fighting MRSA & winning.1,095

Add a New Thread

E-therapeutics (ETX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-12-06 15:59:189.0020,0001,800.96O
2023-12-06 13:28:169.2310,8531,001.98O
2023-12-06 08:17:509.018,880800.09O

E-therapeutics (ETX) Top Chat Posts

Top Posts
Posted at 06/12/2023 08:20 by E-therapeutics Daily Update
E-therapeutics Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker ETX. The last closing price for E-therapeutics was 9.04p.
E-therapeutics currently has 583,844,162 shares in issue. The market capitalisation of E-therapeutics is £52,779,512.
E-therapeutics has a price to earnings ratio (PE ratio) of -6.37.
This morning ETX shares opened at -
Posted at 28/9/2023 14:00 by 1347
What'a this got to do with ETX?
Posted at 25/9/2023 12:42 by maccamcd
Did you listen in on the investor meet presentation a few months ago?I believe it's been mainly one retail investor who's been selling bits continuously...Annoying, but I hope his colour about the opportunity plays out vs one retail seller doing the damage in a tightly held share
Posted at 25/9/2023 12:06 by 1347
Do ETX do anything, or have they become just another placings today, jam tomorrow company? I hope it's not going the same way as DeepMatter, it was a disgrace what happened there and I note Griff is involved in both. Ali needs to get his finger out and let shareholders know what they are doing, if anything.
Posted at 13/7/2023 10:01 by maccamcd
Have you all seen this news???

Recursion Pharmaceuticals (RXRX.NQ) strikes computational drug discovery deal with Nvidia (NVDA.NQ).
• Recursion Pharmaceuticals, an AI drug discovery business, announced a collaboration and $50m equity investment by Nvidia.
• Under the agreement, the partners aim to use Recursion’s biological and chemical datasets to accelerate the training of computational models on Nvidia’s platform.
• These models could be used for commercial license/release on BioNeMo, NVIDIA’s cloud service for generative AI in drug discovery.
• Recursion also expects to use this software to support its internal pipeline and its current and future partners.
The agreement demonstrates the continued interest of generative AI in drug discovery. BioNeMo incorporates large language models (LLMs) into its platform. LLMs, such as Chat GPT-4, are a type of AI trained on large datasets to perform a wide range of tasks, such as generating new hypotheses, predicting protein-protein interactions as well as analysing biomedical literature and patent information at scale.
Although LLMs show promise in improving drug discovery activities, few companies have integrated this technology into their operations. The slow adoption of LLMs in the pharmaceutical industry leaves a significant opportunity for first movers to capture interest in this area. On AIM, ETX is integrating Large Language Models (LLMs) into its own platform.
Posted at 03/7/2023 09:28 by maccamcd
this Companymeet presentation should be informative! Hopefully Ali gives colour on the speed of larger biotech jv interest. At the moment it's hard to quantify what this AI boom really means for ETX in $

You all registered?
Posted at 23/5/2023 14:02 by bloomberg2
ETX get on it while it's under the radar
Posted at 25/10/2021 13:44 by ali47fish
etx reports tomorrow and and a presentation- anyone knows hoot access the latter please
Posted at 18/10/2021 18:51 by 1347
Not aware ETX are running any clinical trails themselves are they, do you have a CT reference? Of course those using their platform(s) may be but not sure what may be imminent on that front.
Posted at 02/8/2021 07:41 by dplewis1
Someone fancies a few ETX shares this morning...
Posted at 04/6/2020 17:14 by paulcon1

I agree but my initial reason for investing was the share price was at 2p, the MKt Value was 6-7 million (approx) and investors were taking advantage of Mr Woodford's misery...

At 21.75p (week back) I thought ETX share price was in unchartered waters and needed a contract to justify the share price . Other posters disagreed...

It is very difficult to place a price on potential and Intellectual Property..

That said, ETX, look to have great technology that could have game-changing possibilities, have a strong team and some wealthy investors seem to be very keen to hoover up shares. The more I read (and partially understand) the more impressed I am with their work and vision.

I bought some shares at 17.25p today... The joys of investing!!

E-therapeutics share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |